| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.64B | 1.59B | 1.56B | 1.44B | 1.31B |
| Gross Profit | 1.10B | 1.15B | 1.06B | 1.04B | 884.02M |
| EBITDA | 1.07B | 1.29B | 1.02B | 966.09M | 1.29B |
| Net Income | 937.29M | 933.68M | 862.57M | 723.37M | 1.08B |
Balance Sheet | |||||
| Total Assets | 27.43B | 25.51B | 24.74B | 24.67B | 22.74B |
| Cash, Cash Equivalents and Short-Term Investments | 149.49M | 156.36M | 140.70M | 248.40M | 365.13M |
| Total Debt | 10.01B | 8.97B | 9.50B | 9.61B | 8.19B |
| Total Liabilities | 10.94B | 9.79B | 10.34B | 10.39B | 9.05B |
| Stockholders Equity | 16.29B | 15.52B | 14.20B | 14.07B | 13.67B |
Cash Flow | |||||
| Free Cash Flow | 867.64M | 865.49M | 961.21M | 896.15M | 733.69M |
| Operating Cash Flow | 868.22M | 1.04B | 1.08B | 1.02B | 827.53M |
| Investing Cash Flow | -742.21M | -520.57M | -38.88M | -926.02M | 256.40M |
| Financing Cash Flow | -132.88M | -507.98M | -1.15B | -214.25M | -902.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | S$18.50B | 18.93 | 6.41% | 5.26% | 0.17% | 8.05% | |
70 Outperform | S$3.62B | ― | 5.16% | 6.46% | 1.47% | -7.50% | |
68 Neutral | S$7.34B | 21.59 | 7.32% | 5.50% | -6.34% | 49.60% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
65 Neutral | S$4.56B | 22.23 | 4.49% | 5.29% | 10.82% | -5.02% | |
62 Neutral | S$4.05B | ― | -0.32% | 4.55% | 0.01% | -110.22% |
CapitaLand Integrated Commercial Trust has secured, via a consortium structure, the tender for a new 99-year mixed-use commercial and residential site at Hougang Central from Singapore’s Housing and Development Board for approximately S$1.5 billion, with CICT’s Commercial Trust to fully develop and own the roughly 300,000 square feet commercial component at an expected development cost of about S$1.1 billion and projected yield on cost above 5%, targeted for completion around 2030/2031. The transaction deepens CICT’s exposure to the stable Singapore market, supports its strategy of growing through development, and strengthens its positioning as a leading vehicle for investors seeking exposure to Singapore’s commercial real estate, potentially enhancing long-term value for its stakeholders through a sizable new suburban commercial hub.
The most recent analyst rating on (SG:C38U) stock is a Buy with a S$2.59 price target. To see the full list of analyst forecasts on CapitaLand Integrated Commercial Trust stock, see the SG:C38U Stock Forecast page.
CapitaLand Integrated Commercial Trust, as part of a consortium, has submitted the highest bid of approximately $1.5 billion for a mixed-use commercial and residential site at Hougang Central, Singapore. The development will integrate with local transport hubs and is expected to feature 830 residential units and 300,000 square feet of retail space, potentially becoming the largest mall in Hougang. This strategic move is set to enhance CICT’s market position by leveraging its expertise in mixed-use developments and expanding its footprint in a key location.
The most recent analyst rating on (SG:C38U) stock is a Buy with a S$2.59 price target. To see the full list of analyst forecasts on CapitaLand Mall stock, see the SG:C38U Stock Forecast page.
CapitaLand Integrated Commercial Trust Management Limited has announced the issuance of 2,955,400 units in CICT to Premier Healthcare Services International Pte Ltd as part of the management fee payment. This issuance represents 50% of the base component of the management fee for the third quarter of 2025, with the remaining fee paid in cash. The issuance does not affect the total number of units held by the company, maintaining its position in the market.
The most recent analyst rating on (SG:C38U) stock is a Buy with a S$2.50 price target. To see the full list of analyst forecasts on CapitaLand Mall stock, see the SG:C38U Stock Forecast page.